Regeneron Pharmaceuticals, Inc. (REGN)
805.02
-14.07
(-1.72%)
USD |
NASDAQ |
Oct 23, 16:00
805.07
+0.05
(+0.01%)
After-Hours: 20:00
Regeneron Pharmaceuticals Enterprise Value : 77.94B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 77.94B |
| October 22, 2026 | 79.40B |
| October 21, 2026 | 78.01B |
| October 20, 2026 | 78.20B |
| October 19, 2026 | 75.56B |
| October 16, 2026 | 76.46B |
| October 15, 2026 | 77.04B |
| October 14, 2026 | 75.18B |
| October 13, 2026 | 72.57B |
| October 12, 2026 | 73.58B |
| October 09, 2026 | 71.89B |
| October 08, 2026 | 71.17B |
| October 07, 2026 | 71.44B |
| October 06, 2026 | 71.09B |
| October 05, 2026 | 69.82B |
| October 02, 2026 | 70.72B |
| October 01, 2026 | 70.68B |
| September 30, 2026 | 73.11B |
| September 29, 2026 | 72.30B |
| September 28, 2026 | 72.48B |
| September 25, 2026 | 76.19B |
| September 24, 2026 | 77.01B |
| September 23, 2026 | 77.61B |
| September 22, 2026 | 77.83B |
| September 21, 2026 | 77.23B |
| Date | Value |
|---|---|
| September 18, 2026 | 75.86B |
| September 17, 2026 | 76.33B |
| September 16, 2026 | 74.80B |
| September 15, 2026 | 74.74B |
| September 14, 2026 | 76.77B |
| September 11, 2026 | 75.51B |
| September 10, 2026 | 76.72B |
| September 09, 2026 | 78.21B |
| September 08, 2026 | 78.49B |
| September 04, 2026 | 80.29B |
| September 03, 2026 | 81.92B |
| September 02, 2026 | 82.80B |
| September 01, 2026 | 79.88B |
| August 31, 2026 | 77.33B |
| August 28, 2026 | 76.82B |
| August 27, 2026 | 78.22B |
| August 26, 2026 | 78.95B |
| August 25, 2026 | 80.89B |
| August 24, 2026 | 80.37B |
| August 21, 2026 | 80.94B |
| August 20, 2026 | 80.18B |
| August 19, 2026 | 81.64B |
| August 18, 2026 | 78.48B |
| August 17, 2026 | 78.03B |
| August 14, 2026 | 77.78B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 280.78B |
| AbbVie, Inc. | 569.05B |
| Biogen, Inc. | 44.10B |
| Incyte Corp. | 18.76B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.297B |
| Revenue (Quarterly) | 4.291B |
| Total Expenses (Quarterly) | 2.994B |
| EPS Diluted (Quarterly) | 12.23 |
| Gross Profit Margin (Quarterly) | 83.68% |
| Profit Margin (Quarterly) | 30.23% |
| Earnings Yield | 5.03% |
| Operating Earnings Yield | 4.84% |
| Normalized Earnings Yield | 5.328 |